Legislative Priorities


The Pancreatic Cancer Action Network calls on the 113th Congress to give current and future pancreatic cancer patients a fighting chance by:

  1. Ensuring that the provisions of the Recalcitrant Cancer Research Act are fully implemented.
  2. Supporting a permanent fix to sequestration and providing sustained adequate funding for the NIH and NCI by:

    • Talking to their leadership, and
    • Delivering a one-minute floor speech citing the growing threat of pancreatic cancer, one of the nation’s deadliest cancers, as an example why Congress must provide adequate sustained funding for lifesaving research through the NIH and the NCI.

The Pancreatic Cancer Action Network has long advocated for ensuring that there is a national strategic plan and accountability for making progress on pancreatic cancer. We applaud Congress for passing the Recalcitrant Cancer Research Act in December 2012. This bill, which was signed into law on January 2, 2013, calls on the NCI to develop scientific frameworks for pancreatic and lung cancer, which will help provide the strategic direction needed to make true progress in these deadly cancers. Under the bill, the director may also develop scientific frameworks for other deadly or recalcitrant cancers, defined as those with a five-year survival rate below 50%. We look forward to updating Congress on the implementation of this important first step in improving pancreatic cancer survival.

While we commend Congress and President Obama for enacting this legislation, our work is far from over. Pancreatic cancer is still the deadliest major cancer with a five-year relative survival rate of just 6 percent and no early detection tools or effective treatments. Further, pancreatic cancer is expected to move from the fourth to the second leading cause of cancer-related death in the U.S. by 2020.

Pancreatic cancer statistics call for aggressive measures now to develop early detection and treatment tools before incidence dramatically increases. Our ability to make progress, however, is hindered by declining medical and cancer research funding. Over the last decade, the NIH has lost approximately 20% of its purchasing power (when factoring in the rate of biomedical inflation). And in fiscal year 2013, the NCI budget was cut by 5.8%, largely as a result of sequestration.

We cannot hope to have success in diseases like pancreatic cancer if current funding trends continue. Further, it will be very difficult to leverage the opportunities that develop as a result of the Recalcitrant Cancer Research Act if funding levels do not improve.

For more information on pancreatic cancer and research funding, click on the buttons below.



Pancreatic cancer is the ONLY major cancer with a five-year survival rate still in the single digits at just 6%.  With your help, we can change this deadly statistic.